Bioventix PLC BVXP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBX 4,425.00
- Day Range
- GBX 4,439.00–4,445.00
- 52-Week Range
- GBX 3,402.00–5,100.00
- Bid/Ask
- GBX 4,400.00 / GBX 4,450.00
- Market Cap
- GBX 23.20 Bil
- Volume/Avg
- 576 / 4,649
Key Statistics
- Price/Earnings (Normalized)
- 28.17
- Price/Sales
- 17.27
- Dividend Yield (Trailing)
- 3.57%
- Dividend Yield (Forward)
- 3.57%
- Total Yield
- 3.57%
Company Profile
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 16
- Website
- http://www.bioventix.com
Comparables
Valuation
|
Metric
|
BVXP
|
ZURA
|
AVCT
|
|---|---|---|---|
Price/Earnings (Normalized) | 28.17 | — | — |
Price/Book Value | 20.20 | 2.66 | 5.39 |
Price/Sales | 17.27 | — | 7.34 |
Price/Cash Flow | 25.71 | — | — |
Price/Earnings
BVXP
ZURA
AVCT
Financial Strength
|
Metric
|
BVXP
|
ZURA
|
AVCT
|
|---|---|---|---|
Quick Ratio | 6.69 | 4.92 | 0.66 |
Current Ratio | 7.04 | 4.97 | 0.71 |
Interest Coverage | — | — | −3.70 |
Quick Ratio
BVXP
ZURA
AVCT
Profitability
|
Metric
|
BVXP
|
ZURA
|
AVCT
|
|---|---|---|---|
Return on Assets (Normalized) | 68.76% | −71.08% | −41.74% |
Return on Equity (Normalized) | 77.21% | −139.85% | −122.29% |
Return on Invested Capital (Normalized) | 76.10% | −99.89% | −53.10% |
Return on Assets
BVXP
ZURA
AVCT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Kzwrwyzcm | Ptb | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Sslmlythn | Vxjkd | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rzqydkc | Bvdjr | $97.8 Bil | |
MRNA
| Moderna Inc | Jqppskwb | Ygt | $38.8 Bil | |
ARGX
| argenx SE ADR | Gdvtfrpp | Bhn | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Vgbtszz | Pptm | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Stbmtby | Vhlgjv | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dsptdsr | Gpypfd | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Kprnkdsbx | Cskzx | $12.5 Bil | |
INCY
| Incyte Corp | Pzmncgc | Ypfjtpt | $11.5 Bil |